10x Genomics and Cliseq Ltd. to investigate single cell applications

10x Genomics (TXG) announced a translational research collaboration with Cliseq Ltd., a translational diagnostics company spun out of Yeda, the commercial arm of the Weizmann Institute of Science, and the Weizmann Institute. Together, the organizations are launching a multi-year, international clinical research study to investigate the use of peripheral single cell RNA sequencing as a minimally invasive, clinically viable alternative to bone marrow aspiration for diagnosing hematologic disorders. The research study will compare single cell profiles from peripheral blood with conventional bone marrow aspirations results to determine the viability and advantages of a minimally invasive approach for identifying Myelodysplastic Syndromes and other hematology disorders. Cliseq has acquired exclusive rights to this technology through Yeda, the Weizmann Institute’s commercialization arm. The study will leverage 10x Genomics’ Chromium GEM-X Single Cell technology to examine thousands of individual cells in each blood sample. This collaboration marks one of the first international clinical research programs to evaluate single cell transcriptomics in a real-world context.